Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.55 |
| ▸ | NPC1 | O15118 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | MAOB | P27338 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30065409 | 0.87 | KDM4E (0.55) | RAB9ASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL10060679 | 0.87 | KDM4E (0.55) | RAB9ASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL285908 | 0.87 | KDM4E (0.55) | RAB9ANPC1KDM4EALDH1A1MAOB | |
| SCHEMBL3213436 | 0.84 | RECQL (0.61) | RAB9ANPC1SMN1; SMN2MAPTKDM4E | |
| SCHEMBL7427750 | 0.84 | MAOB (0.69) | RAB9ASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL17967638 | 0.84 | MAOB (0.53) | RAB9ASMN1; SMN2MAPTPOLBKDM4E | |
| SCHEMBL20460424 | 0.84 | KMT2A (0.52) | RAB9ANPC1SMN1; SMN2POLBKDM4E | |
| SCHEMBL10707454 | 0.84 | KDM4E (0.56) | RAB9ASMN1; SMN2POLBKDM4EALDH1A1 | |
| SCHEMBL16393962 | 0.84 | LMNA (0.51) | SMN1; SMN2POLBKDM4EALDH1A1L3MBTL1 | |
| SCHEMBL21531034 | 0.83 | CYP1A2 (0.57) | SMN1; SMN2POLBKDM4EALDH1A1MAOB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2662357-B1 | BICYCLIC COMPOUNDS OR SALTS THEREOF FOR USE IN THE TREATMENT OF CANCER | TAIHO PHARMACEUTICAL CO LTD (JP) | 2016-08-03 | — | — | EP | disclosed |
| US-8912181-B2 | Bicyclic compound or salt thereof | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2014-12-16 | — | — | US | disclosed |
| EP-2662357-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2013-11-13 | — | — | EP | disclosed |
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | TAIHO PHARMACEUTICAL CO., LTD. (JP) | 2013-11-07 | — | — | US | disclosed |
| US-20070066624-A1 | Chemokine receptor binding compounds | ANORMED, INC. (CA) | 2007-03-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130296320-A1 | NOVEL BICYCLIC COMPOUND OR SALT THEREOF | HSP90AB1, HSP90AA1, HSP90AB2P | RAB9A 979/4885NPC1 1614/4885SMN1; SMN2 4579/4885 |
| US-20070066624-A1 | Chemokine receptor binding compounds | CCR5, CCR4, CCR1 | RAB9A 2707/4885NPC1 473/4885SMN1; SMN2 4729/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.